NT-3-Expressing BMSCs Treatment: Promoting Remyelination to Reduce Aβ Amyloid Production

Le résumé fourni par la source

Alzheimer’s disease (AD) is a progressive neurodegenerative disease whose core pathology includes amyloid-β (Aβ) plaques. The current studies have proved that myelin dysfunction is the upstream factor of Aβ deposition, which provides a new target for the prevention and treatment of AD. Nevertheless, no effective therapeutic strategy currently exists to halt or repair myelin damage. Bone marrow mesenchymal stem cells (BMSCs) are recognized as highly promising for adult stem cell therapy in neurological conditions, given their accessibility, rapid expansion, genetic adaptability, and feasibility for autologous grafting. Neurotrophin-3 (NT-3) is critically involved in the growth, differentiation, and maturation of oligodendrocyte lineages and promotes oligodendrocyte progenitor cell (OPC) maturation and myelination, highlighting its therapeutic potential. This study attempts to explore whether the use of NT-3-modified BMSC to promote myelin regeneration can reduce Aβ production and aims to find potential therapeutic approaches to improve the efficacy of treating degenerative disorders of the nervous system, with Alzheimer’s disease as a prime example.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.